Building on this foundation, our purpose is to drive change to defeat serious chronic diseases from diabetes and obesity to rare blood and endocrine disorders by pioneering scientific breakthroughs, expanding access to medicines, and working to prevent and ultimately cure disease
The GIP + GLP-1 Blend is carefully personalized for each patient by a U.S.-licensed provider
While most users without prior mental health conditions tolerate semaglutide well, individual genetic variations and the stress of rapid metabolic change can trigger mood symptoms in susceptible individuals
In STEP-1 (N=1,961), patients began losing weight in the first four weeks
As new data emerges, clinicians must stay informed and adapt their practices accordingly
Graziano F, Renato B, Catalano V, and et al